Open AccessOsteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial
Author(s) -
Ueland Thor,
Åkerblom Axel,
Ghukasyan Tatevik,
Michelsen Annika E.,
Aukrust Pål,
Becker Richard C.,
Bertilsson Maria,
Himmelmann Anders,
James Stefan K.,
Siegbahn Agneta,
Storey Robert F.,
Kontny Frederic,
Wallentin Lars
Publication year - 2018
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.007009
Subject(s) - medicine , osteoprotegerin , hazard ratio , myocardial infarction , cardiology , clinical endpoint , proportional hazards model , coronary artery disease , stroke (engine) , confidence interval , randomized controlled trial , receptor , mechanical engineering , activator (genetics) , engineering
Elevated levels of osteoprotegerin, a secreted tumor necrosis factor-related molecule, might be associated with adverse outcomes in patients with coronary artery disease. We measured plasma osteoprotegerin concentrations on hospital admission, at discharge, and at 1 and 6 months after discharge in a predefined subset (n=5135) of patients with acute coronary syndromes in the PLATO (Platelet Inhibition and Patient Outcomes) trial.